Central signaling response found in mitochondrial energy diseases

July 24, 2013

Researchers have identified a master network of signaling molecules that acts like a "fuse box" to regulate the cellular effects of defective energy flow in mitochondrial respiratory chain diseases—a diverse set of difficult-to-treat genetic-based energy disorders. Using that knowledge, they showed that nicotinic acid, a form of vitamin B3, partially restores normal functioning in cells taken from patients with mitochondrial disease.

The study, from The Children's Hospital of Philadelphia (CHOP), suggests that the regulatory network may offer a common avenue to target in the developing effective, personalized treatments for many mitochondrial energy disorders.

Mitochondria are tiny that act as cellular power plants, extracting energy from nutrients to drive the body. When mitochondria malfunction, they may impair the function of potentially any organ throughout the body, in an often bewildering variety of ways. Mitochondrial disease can have widely varying effects and severity in different tissues, ranging from blindness to exercise intolerance to death, often wreaking progressive havoc over time in both children and adults.

"Finding a common reveals that some order exists in the chaos of these basic energy diseases," said study leader Marni J. Falk, M.D., director and attending physician in the Mitochondrial-Genetic Disease Clinic at CHOP. "Identifying the central factors regulating manifestations of mitochondrial disease is like troubleshooting a household electrical system: instead of analyzing problems that may occur at each individual light bulb or switch plate, we have located a central problem in the fuse box."

Falk and colleagues published their study today in the journal PLOS ONE.

Primary mitochondrial diseases directly interfere with the function of the respiratory chain (RC)—the highly conserved sequence of within mitochondria that generate energy from oxygen and nutrients.

"There are hundreds of different individual reasons for RC malfunction," said Falk, "but we identified a common cellular response—an integrated, nutrient-sensing signaling network—that recognizes when energy flow is impaired. That response alters a host of biological pathways, and in many tissues, those secondary biochemical changes are actually contributing to the symptoms of disease."

RC malfunction in mitochondrial disease may cause symptoms such as seizures, strokes, blindness, heart disease, progressive muscle weakness, or vulnerability to infections, among other problems. No cure exists, and most current treatments for RC diseases are largely ineffective.

In the current study, Falk and colleagues analyzed cellular responses in human skeletal muscle and skin cell lines, finding that RC disease disrupted crucial biological pathways controlled by a handful of master signaling factors: FOXO, PPAR, sirtuins, AMPK, and mTORC1. All of these factors are integral components of cellular signaling networks that sense nutrient availability and regulate growth.

"The good news in our research is that the signaling pathways regulating the body's response to mitochondrial disease are already well-known for other reasons," said Falk. "Using an agent that restores their collective activity toward more normal functioning offers potential treatments for the diverse symptoms of mitochondrial RC disease."

Building on her team's previous animal studies, showing that a cholesterol-lowering drug called probucol restored kidney function in a mouse model of an RC defect, Falk and colleagues used X a form of vitamin B3, nicotinic acid, in their current study. Like probucol, nicotinic acid is known to stimulate the PPAR signaling pathway. Here, they added nicotinic acid to a fibroblast cell line grown from the skin of a patient with the mitochondrial disease known as Leigh syndrome that causes strokes in young children.

The results, said Falk, were exciting. The nicotinic acid normalized signaling activity not just in PPAR, but across an integrated signaling network, and also improved overall cellular respiration—the cells' ability to use oxygen. "Even though the underlying genetic defect in RC function persisted, we were able to reverse some of its major deleterious downstream effects on crucial cellular functions that are impaired in many varieties of mitochondrial disease."

Falk cautioned that much work remains to be done, including studies in animal models, to determine if this discovery in patient tissues and cell culture may lead to effective clinical treatments. But, she added, "finding a central signaling mechanism common to highly diverse RC disease should allow researchers to better classify subtle differences in this signaling response to understand subtypes and fashion personalized treatments that restore specific signaling alterations identified in individual patients."

Explore further: Animal results may pave way to treating rare mitochondrial diseases in children

More information: PLOS ONE, published online July 24, 2013. DOI: 10.1371/journal.pone.0069282

Related Stories

Animal results may pave way to treating rare mitochondrial diseases in children

May 19, 2011
A human drug that both prevents and cures kidney failure in mice sheds light on disabling human mitochondrial disorders, and may represent a potential treatment in people with such illnesses.

Scientists create one-step gene test for mitochondrial diseases

January 29, 2013
More powerful gene-sequencing tools have increasingly been uncovering disease secrets in DNA within the cell nucleus. Now a research team is expanding those rapid next-generation sequencing tests to analyze a separate source ...

Rare mitochondrial mutations—maybe not so rare?

June 8, 2013
French scientists have discovered that supposedly rare mutations in the mitochondria, the 'power plants' of human cells responsible for creating energy, account for more than 7% of patients with a mitochondrial disease manifesting ...

How mitochondrial DNA defects cause inherited deafness

February 17, 2012
(Medical Xpress) -- Yale scientists have discovered the molecular pathway by which maternally inherited deafness appears to occur: Mitochondrial DNA mutations trigger a signaling cascade, resulting in programmed cell death. ...

Discovery may lead to mitochndria syndrome treatment

September 22, 2011
Mitochondrial depletion syndrome accounts for about 11 percent of the cases of children born with common myopathies and a more mild form of the syndrome affecting adults. A new finding by Cornell researchers may lead to a ...

Recommended for you

Green tea ingredient may ameliorate memory impairment, brain insulin resistance, and obesity

July 28, 2017
A study published online in The FASEB Journal, involving mice, suggests that EGCG (epigallocatechin-3-gallate), the most abundant catechin and biologically active component in green tea, could alleviate high-fat and high-fructose ...

Study finds walnuts may promote health by changing gut bacteria

July 28, 2017
Research led by Lauri Byerley, PhD, RD, Research Associate Professor of Physiology at LSU Health New Orleans School of Medicine, has found that walnuts in the diet change the makeup of bacteria in the gut, which suggests ...

Manipulating a type of brain cell gets weight loss results in mice

July 28, 2017
A new study has found something remarkable: the activation of a particular type of immune cell in the brain can, on its own, lead to obesity in mice. This striking result provides the strongest demonstration yet that brain ...

Team finds link between backup immune defense, mutation seen in Crohn's disease

July 27, 2017
Genes that regulate a cellular recycling system called autophagy are commonly mutated in Crohn's disease patients, though the link between biological housekeeping and inflammatory bowel disease remained a mystery. Now, researchers ...

Study finds harmful protein on acid triggers a life-threatening disease

July 27, 2017
Using an array of modern biochemical and structural biology techniques, researchers from Boston University School of Medicine (BUSM) have begun to unravel the mystery of how acidity influences a small protein called serum ...

CRISPR sheds light on rare pediatric bone marrow failure syndrome

July 27, 2017
Using the gene editing technology CRISPR, scientists have shed light on a rare, sometimes fatal syndrome that causes children to gradually lose the ability to manufacture vital blood cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.